N . Jabayeva et al .: J Extra Corpor Technol 2024 , 56 , 45 – 54 53
Q6 Table 4 . Extracorporeal blood purification procedures .
|
|
Quantity of procedures |
|
Type of procedure |
HA330 group n = 20 |
CytoSorb-300 group ( n = 20 ) |
Control group ( n = 20 ) |
CVVHF , mean ( range ) |
1 |
0 |
4 |
CVVHDF , mean ( range ) |
5 |
4 |
5 |
CVVHD , mean ( range ) |
1 |
0 |
6 |
OL-HDF , mean ( range ) |
17 |
16 |
23 |
OL-HF , mean ( range ) |
1 |
8 |
6 |
Intermittent HD , mean ( range ) |
0 |
0 |
16 |
SLED , mean ( range ) |
1 |
0 |
1 |
HP ( HA 280 ), mean ( range ) |
2 |
0 |
0 |
HP ( HA330II ), mean ( range ) |
0 |
2 |
6 |
Total number of procedures |
28 |
30 |
67 |
CVVHF – Continuous Veno-Venous Hemofiltration ; CVVHDF – Continuous venovenous hemodiafiltration ; CVVHD – Continuous venovenous hemodialysis ; OL-HDF – Online haemodiafiltration ; OL-HF – Online hemofiltration ; Intermittent HD – Intermittent hemodialysis ; SLED – sustained low-efficiency dialysis ; HP ( HA 280 ) – hemoperfusion cartridge HA 280 ; HP ( HA330II ) – hemoperfusion cartridge HA 330 II . lower levels of IL-6 , CRP , and leucocytes . However , the differences in cytokine levels between patients who received haemosorption and control were not significant and the effect was not long-lasting . HA therapy did not significantly reduce the risk of CSA-AKI after long-term CPB , but it more than halved the need for substitution therapy .
Funding
This research has been funded by the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan ( Grant No . AP09258870 , BR10965200 ) ( https :// www . ncste . kz / en / main ). The funders had no role in study design , data collection and analysis , decision to publish , or preparation of the manuscript .
Conflicts of Interest The authors declare no conflict of interest .
Data availability statement
The data presented in this study is available upon request from the corresponding author .
Author contribution statement
Nilufar Jabayeva – data collection ; Bolat Bekishev – data collection ; Timur Lesbekov – data analysis / interpretation , critical revision of article ; Zhuldyz Nurmykhametova – data analysis / interpretation , critical revision of article , data collection ; Rymbay Kaliyev – concept / design , approval of article ; Linar Faizov – concept / design ; Aidyn Kuanyshbek – approval of article , and Robertas Samalavicius – critical revision of article , approval of article .
Ethics approval
The study was conducted in accordance with the Declaration of Helsinki , and approved by the Local Bioethics Committee of the National Research Cardiac Surgery Center ( No . 01-74 / 2021 from 10 / 06 / 20 ).
Informed consent statement
Informed consent was obtained from all subjects involved in the study .
Supplementary material
The supplementary material of this article is available at https :// ject . edpsciences . org / 10.1051 / ject / 2024004 / olm Supplementary Table : Characteristics of the CytoSorb300 and HA 330 cartridges .
References
1 . Quaniers JM , Leruth J , Albert A , Limet RR , Defraigne J-O . Comparison of inflammatory responses after off-pump and onpump coronary surgery using surface modifying additives circuit . Ann Thorac Surg 2006 ; 81 ( 5 ): 1683 – 1690 .
2 . Melek FE , Baroncini LAV , Repka JCD , Nascimento CS , PrécomaPrécoma DB . Oxidative stress and inflammatory response increase during coronary artery bypass grafting with extracorporeal circulation . Rev Bras Cir Cardiovas 2012 ; 27 ( 1 ): 61 – 65 .
3 . Clive Landis R , Murkin JM , Stump DA , et al . Consensus statement : Minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass . Heart Surg Forum 2010 ; 13 : E116 – E123 .
4 . Rubens FD , Nathan H , Labow R , et al . Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass . Ann Thorac Surg 2005 ; 79 ( 2 ): 655 – 665 .
5 . He Z , Lu H , Jian X , et al . The efficacy of resin hemoperfusion cartridge on inflammatory responses during adult cardiopulmonary bypass . Blood Purif 2022 ; 51 ( 1 ): 31 – 37 .
6 . Warren AL , de Watret KL , Wit , et al . The inflammatory response to cardiopulmonary bypass : part 2-Anti-inflammatory therapeutic strategies . J Cardiothor Vasc Anesth 2009 ; 23 ( 3 ): 384 – 393 .
7 . Morariu AM , Loef BG , Aarts LPHJ , et al . Dexamethasone : benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting . Chest 2005 ; 128 ( 4 ): 2677 – 2687 .